Head to Head Comparison: Hancock Jaffe Laboratories (NASDAQ:HJLI) versus Invivo Therapeutics (NASDAQ:NVIV)

Hancock Jaffe Laboratories (NASDAQ:HJLI) and Invivo Therapeutics (NASDAQ:NVIV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, valuation, institutional ownership, earnings and dividends.

Volatility & Risk

Hancock Jaffe Laboratories has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500. Comparatively, Invivo Therapeutics has a beta of 1.54, indicating that its stock price is 54% more volatile than the S&P 500.

Profitability

This table compares Hancock Jaffe Laboratories and Invivo Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Hancock Jaffe Laboratories -5,250.79% -207.10% -124.79%
Invivo Therapeutics N/A -78.39% -65.23%

Earnings & Valuation

This table compares Hancock Jaffe Laboratories and Invivo Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Hancock Jaffe Laboratories $190,000.00 69.79 -$13.04 million N/A N/A
Invivo Therapeutics N/A N/A -$23.42 million ($2.25) -0.17

Hancock Jaffe Laboratories has higher revenue and earnings than Invivo Therapeutics.

Insider & Institutional Ownership

1.3% of Hancock Jaffe Laboratories shares are held by institutional investors. Comparatively, 7.2% of Invivo Therapeutics shares are held by institutional investors. 0.3% of Invivo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings for Hancock Jaffe Laboratories and Invivo Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hancock Jaffe Laboratories 0 0 1 0 3.00
Invivo Therapeutics 0 0 0 0 N/A

Hancock Jaffe Laboratories presently has a consensus price target of $3.00, indicating a potential upside of 305.41%. Given Hancock Jaffe Laboratories’ higher probable upside, research analysts clearly believe Hancock Jaffe Laboratories is more favorable than Invivo Therapeutics.

Summary

Invivo Therapeutics beats Hancock Jaffe Laboratories on 6 of the 10 factors compared between the two stocks.

About Hancock Jaffe Laboratories

Hancock Jaffe Laboratories, Inc., a development stage medical device company, develops and sells biological tissue solutions to treat patients with coronary, vascular, end stage renal, and peripheral arterial diseases in the United States and Europe. The company develops and manufactures implantable cardiovascular bioprosthetic devices for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease. Its products include the Bioprosthetic Heart Valve, a bio-prosthetic heart valve designed to mimic and function like a native heart valve; the CoreoGraft, a device for use as an alternate or supplemental coronary vascular conduit in coronary bypass surgery; and the Venous Valve, a bioprosthetic, pig venous valve for patients with lower limb chronic venous insufficiency. The company was founded in 1987 and is headquartered in Irvine, California. As of July 18, 2006, Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA.

About Invivo Therapeutics

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord. InVivo Therapeutics Holdings Corp. has research collaboration with the Q Therapeutics, Inc. for the evaluation of the combination of PLGA-PLL based Neuro-Spinal Scaffold with adult neural progenitor cells, including those from induced pluripotent stem cells. The company was founded in 2005 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Hancock Jaffe Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hancock Jaffe Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.